In addition, discrepancies in study outcomes and adverse event profiles underscore the need for further research to elucidate the efficacy and optimal use of GLP-1 RAs in reducing alcohol consumption in individuals with AUD, obesity, and liver disease. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.